Advantx Pharmaceuticals is a New York-based clinical-stage biopharmaceutical company focused on
advanced therapies for neurological disorders and neurodegenerative diseases.
REVOLUTIONIZING THE TREATMENT OF CNS CONDITIONS
Unique Platform: Advantx Pharmaceuticals is a clinical-stage biotech company with a proprietary platform of pharmaceutical-grade compounds for neurologic disorders and neurodegenerative diseases. Our unique approach offers advantages in terms of neuronal modulation, brain penetration, oral bioavailability, and manufacturing scalability.
Unlocking the Potential of Sigma Proteins: Sigma proteins, a unique evolutionary isolate distinct from any other human proteins, represent the pinnacle of protein evolution. As the unique ligand-operated chaperone receptor proteins, they play a crucial role in neuronal health.
Unraveling the Complexity of human diseases: Advantx Pharmaceuticals has taken the forefront in unraveling the complex nature of human diseases, delving into the intricate details of neuronal health and harnessing their immense potential in addressing a wide range of degenerative, life-threatening, and incurable conditions.
Advantx’s Unique Approach: By precisely modulating specific proteins, our innovative therapies target multiple disease-causing pathways while normalizing the homeostasis of key proteins and cells under stress or DNA damage, and regulating key transcription factors. This genomic precision enables us to positively modify the course of various conditions while minimizing undesirable side effects.
Groundbreaking clinical progress: With an accelerated biomarker-based clinical development approach, we bring our therapies to patients swiftly, safely, and effectively. Our robust patent portfolio secures worldwide rights to our products until 2041, ensuring the continued advancement of our innovative treatments.
Our pipeline
Potential market for Advantx candidates
Advantx Pipeline
Six ProgramsTarget Population
>35m patientsTotal Addressable Market
>$17B TAMMarket Growth
>10.5% CAGRsource: Globaldata
The Advantx Pharmaceuticals Advantage
Harnessing the Genetic Power of Sigma Ligands
THE NEURONAL ADVANTAGE
Advantx Pharmaceuticals is at the forefront of leveraging cutting-edge engineering to develop new chemical entities (NCEs). These are precise, pharma-quality compounds specifically designed to target unique receptors within neurons. Our innovative therapies modulate distinct cellular pathways, aiming to restore both proteostasis and neuronal homeostasis. By directly targeting these intracellular mechanisms, our small-molecule offer a compelling advantage in efficacy over biologics, which generally act outside the cell.
THE GENETIC ADVANTAGE
At Advantx Pharmaceuticals, we leverage our deep understanding of key regulatory genes to develop advanced therapies. This enables us to unlock the potential of pluripotent proteins like Sigma, which are critical in modulating functional pathways, proteostasis, gene transcription, and cellular homeostasis. Our innovative disease-modifying therapies are designed to restore proper cellular function and neuronal health with genetic precision and using genomic biomarkers to expedite the development of our portfolio.
Advantx Candidate
ADV462 EAD
Early Alzheimer’s Disease
Selective Sigma-2
Potent Antagonist
Positive Results.